文献速递骨软组织肉瘤与黑色素瘤

应用基因工程鼠伤寒沙门菌进行干扰素-γ诱导的黑色素瘤治疗

Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma.
PubMed 文献 · Eur J Cancer · 2016-11-22

研究将减毒鼠伤寒沙门菌基因改造以表达并分泌干扰素-γ(IFN-γ),体外可侵入黑色素瘤细胞并诱导细胞毒性;在B16F10黑色素瘤C57BL/6小鼠中,皮下给药可抑制肿瘤生长并延长生存,呈自然杀伤(NK)细胞依赖性,且对正常组织毒性低。

要点

  • 表达分泌IFN-γ的减毒鼠伤寒沙门菌可侵入黑色素瘤细胞并诱导细胞毒性。
  • 皮下给药抑制B16F10荷瘤C57BL/6小鼠肿瘤生长并延长生存,呈NK细胞依赖性。
  • 该菌对正常组织毒性低,未见可观察的不良反应;肿瘤抑制归因于直接杀伤肿瘤细胞而非稳定抗肿瘤免疫。

核心结论

  • 结果表明,使用表达IFN-γ的鼠伤寒沙门菌进行肿瘤靶向治疗对黑色素瘤治疗具有潜力。

研究设计与样本

  • 研究对减毒鼠伤寒沙门菌进行基因改造,使其表达并分泌IFN-γ;IFN-γ与SipB N端区域(残基1-160,SipB160)融合以从细菌细胞分泌。
  • 体外用表达重组IFN-γ的减毒鼠伤寒沙门菌(S. typhimurium (IFN-γ))侵染黑色素瘤细胞并评估细胞毒性。
  • 体内在B16F10黑色素瘤C57BL/6小鼠中皮下给药,与磷酸盐缓冲液(PBS)、未修饰鼠伤寒沙门菌或表达空载体的鼠伤寒沙门菌(S. typhimurium [Vec])比较。

主要发现

  • 表达重组IFN-γ的减毒鼠伤寒沙门菌侵染黑色素瘤细胞并诱导细胞毒性。
  • 皮下给药S. typhimurium (IFN-γ)较PBS、未修饰鼠伤寒沙门菌或S. typhimurium (Vec)有效抑制B16F10荷瘤C57BL/6小鼠的肿瘤生长并延长生存,呈NK细胞依赖性。
  • 包括S. typhimurium (IFN-γ)在内的基因改造沙门菌对正常组织毒性低,未见可观察的不良反应。
  • S. typhimurium (IFN-γ)介导的肿瘤抑制归因于直接杀伤肿瘤细胞,而非稳定的抗肿瘤免疫。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Salmonella have been experimentally used as anti-cancer agents, because they show selective growth in tumours. In this study, we genetically modified attenuated Salmonella typhimurium to express and secrete interferon-gamma (IFN-γ) as a tumouricidal agent to enhance the therapeutic efficacy of Salmonella. IFN-γ was fused to the N-terminal region (residues 1-160) of SipB (SipB160) for secretion from bacterial cells. Attenuated S. typhimurium expressing recombinant IFN-γ (S. typhimurium (IFN-γ)) invaded the melanoma cells and induced cytotoxicity. Subcutaneous administration of S. typhimurium (IFN-γ) also efficiently inhibited tumour growth and prolonged the survival of C57BL/6 mice bearing B16F10 melanoma compared with administration of phosphate-buffered saline (PBS), unmodified S. typhimurium or S. typhimurium expressing empty vector (S. typhimurium [Vec]) in a natural killer (NK) cell-dependent manner. Moreover, genetically modified Salmonella, including S. typhimurium (IFN-γ), showed little toxicity to normal tissues with no observable adverse effects. However, S. typhimurium (IFN-γ)-mediated tumour suppression was attributed to direct killing of tumour cells rather than to stable anti-tumour immunity. Collectively, these results suggest that tumour-targeted therapy using S. typhimurium (IFN-γ) has potential for melanoma treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yoon W, Park YC, Kim J, et al. Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma. Eur J Cancer. 2016. PMID: 27883926. doi:10.1016/j.ejca.2016.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。